dc.rights.license | CC-BY-NC-ND | |
dc.contributor.advisor | Heidenreich, Olaf | |
dc.contributor.author | Mohnani, Rebecca | |
dc.date.accessioned | 2023-09-28T23:00:57Z | |
dc.date.available | 2023-09-28T23:00:57Z | |
dc.date.issued | 2023 | |
dc.identifier.uri | https://studenttheses.uu.nl/handle/20.500.12932/45250 | |
dc.description.abstract | Tandem duplications in the upstream binding transcription factor (UBTF-TD) have been recently identified as a recurrent mutation in pediatric acute myeloid leukemia (AML). They are seen in 4% of de novo patients and 9% of relapse cases. Transcriptionally similar AML subtypes, such as MLL-rearranged, NUP98- rearranged, and NPMI-mutant AMLs, were found to respond to small molecular inhibitors to the menin-MLL1 interaction which is critical for leukemogenesis. We hypothesized that due to similarities in the oncogenic programs of these AML subtypes with AMLs harboring the UBTF-TD alteration, implementation of Menin inhibitors could lead to a reduction in the leukemic characteristic of UBTF-TD AMLs. This hypothesis was tested by treating primary UBTF-TD AML cells with the Menin inhibitor SNDX-5613 (Revumenib) and looking at its effect on global gene expression via RT-qPCR and RNA sequencing. Since UBTF-TD AMLs are often accompanied by FLT3-ITDs, we also looked at the effect of SNDX-5613 and its combination with an FLT3 inhibitor on this protein through phopho-STAT5 signaling pathway analysis. We found that Menin inhibition substantially changed global gene expression of UBTF-TD AMLs, including downregulation of important downstream target genes that depend upon the Menin-MLL interaction and upregulation of differentiation markers. Phospho-STAT5 signaling analyzed by flow cytometry revealed that individual treatment was as effective (Gilteritinib) or more effective (SNDX-5613) than combination treatment. | |
dc.description.sponsorship | Utrecht University | |
dc.language.iso | EN | |
dc.subject | UBTF tandem duplication (UBTF-TD) is a recently discovered recurrent mutation in Acute Myeloid Leukemia (AML) which shares transcriptional and mutational backgrounds with MLL-r NPM1 and NUP98r AMLs. The aim of this project is to investigate the sensitivity of AML cells possessing a UBTF-TD to the Menin inhibitor SNDX-5613. The performed experiments display that Menin inhibition, in this case via SNDX-5613, offers a potential treatment strategy for UBTF-TD AMLs. | |
dc.title | New Treatment Opportunity for Acute Myeloid Leukemias Harbouring a UBTF Tandem Duplication | |
dc.type.content | Master Thesis | |
dc.rights.accessrights | Open Access | |
dc.subject.courseuu | Cancer, Stem Cells and Developmental Biology | |
dc.thesis.id | 24822 | |